METASTATIC COLORECTAL CARCINOMA
Clinical trials for METASTATIC COLORECTAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC COLORECTAL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC COLORECTAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo aims to starve and attack tumors
Disease control OngoingThis early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors that have spread. The main goal is to find the safes…
Matched conditions: METASTATIC COLORECTAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
New hope for hard-to-treat colorectal cancer: drug duo targets tumor defenses
Disease control OngoingThis study tests a combination of two drugs—SX-682 and nivolumab—in people with a specific type of advanced colorectal cancer (RAS-mutated, MSS) that has spread or can't be removed. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 51…
Matched conditions: METASTATIC COLORECTAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
Microwave vs. scalpel: new study tests safer lung tumor treatment
Disease control OngoingThis study compares two treatments for lung lesions in people with non-small cell lung cancer, sarcoma, or colorectal cancer that has spread. One treatment uses microwave energy to heat and kill tumor cells, while the other is a small surgery to remove the tumor. Researchers want…
Matched conditions: METASTATIC COLORECTAL CARCINOMA
Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:01 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in people with advanced solid tumors that have spread or can't be removed by surgery. The main goal is to find the safest dose and check for side effects. About 66 adults with cance…
Matched conditions: METASTATIC COLORECTAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New combo therapy aims to shrink metastatic tumors in lung and colon cancer
Disease control OngoingThis study tests two immunotherapy drugs, durvalumab and tremelimumab, alone or combined with low or high-dose radiation, in people with metastatic colorectal or non-small cell lung cancer. The goal is to see if adding radiation helps the drugs work better to shrink tumors. About…
Matched conditions: METASTATIC COLORECTAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New drug cocktail shows promise for Tough-to-Treat colorectal cancer
Disease control OngoingThis study tests whether adding two targeted drugs (LY3214996 and abemaciclib) to the standard drug cetuximab can shrink tumors or slow cancer growth in people with advanced colorectal cancer that no longer responds to cetuximab alone. About 46 adults with metastatic or inoperabl…
Matched conditions: METASTATIC COLORECTAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New combo therapy targets hard-to-treat HER2 cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a cell-growth blocker)—in people with advanced solid tumors that have a HER2 mutation. The study first finds the safest dose, then compares the combo against…
Matched conditions: METASTATIC COLORECTAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New immune cell therapy targets five Hard-to-Treat cancers
Disease control TerminatedThis early-stage trial was designed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. The treatment uses a patient's own immune cells (T cells) taken fro…
Matched conditions: METASTATIC COLORECTAL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 05, 2026 11:53 UTC